The SPAC secured shareholder approval for the deal last week with 84.3% redemptions. Graf IV CEO James Graf is set to join the combined company as its interim CFO.
The $160 million combination was initially announced in April of this year. Santa Ana, California-based NKGen has five pharmaceutical formulas that have each reached some stage of Phase I and Phase II clinical trials seeking potential therapies for cancer and neurodegenerative conditions like Parkinson’s and Alzheimer’s.
The company expects to release interim data from its Phase I trials for drug candidate SNK-02 for solid tumor treatments before the end of 2023.
- Cooley LLP is acting as legal advisor to NKGen and NKMax.
- White & Case LLP is acting as legal advisor to Graf.